Upregulated microRNA-199a-5p inhibits nuclear receptor corepressor 1 translation in mice with non-alcoholic steatohepatitis

Molecular Medicine Reports

Volumn 10, Issue 6, 2014, Pages 3080-3086

  Zhang, Binggui ^a   Wang, Rongqi ^a   Du, Jinghua ^a   Niu, Jingya ^b   Zhang, Rui ^a   Xu, Shunjiang ^a   Niu, Xuemin ^a   Zhang, Qingfu ^a   Nan, Yuemin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Provincial Geriatric Hospital   (China)

Author keywords

Bioinformatic analysis; Methionine choline deficient; MicroRNA 199a 5p; Non alcoholic steatohepatitis; Nuclear receptor corepressor 1

Indexed keywords

MUS;

INSULIN; MICRORNA; MIRN199 MICRORNA, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; NCOR1 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN 140;

ANIMAL; BIOLOGY; C57BL MOUSE; CELL PROLIFERATION; GENETICS; LIVER; MALE; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; PROCEDURES; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASES; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR RECEPTOR CO-REPRESSOR 1; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84914145440     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2592     Document Type: Article

References (47)

1. Adams LA, Lymp JF, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129: 113-121, 2005.
2. Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43 (2 Suppl 1): S99-S112, 2006.
3. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G and Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14: 72-81, 2008.
4. Zhang BH, Weltman M and Farrell GC: Does steatohepatitis impair liver regeneration? A study in a dietary model of non-alcoholic steatohepatitis in rats. J Gastroenterol Hepatol 14: 133-137, 1999.
5. Rinella ME, Elias MS, Smolak RR, et al: Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49: 1068-1076, 2008.
6. Sutti S, Jindal A, Locatelli I, et al: Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology 59: 886-897, 2014.
7. Pogribny IP and Beland FA: Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease. Expert Opin Drug Metab Toxicol 9: 713-724, 2013.
8. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
9. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
10. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
11. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.
12. Najafi-Shoushtari SH, Kristo F, Li Y, et al: MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328: 1566-1569, 2010.
13. El Ouaamari A, Baroukh N, Martens GA, et al: MiR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 57: 2708-2717, 2008.
14. Shan Y, Zheng J, Lambrecht RW and Bonkovsky HL: Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133: 1166-1174, 2007.
15. Ogawa T, Enomoto M, Fujii H, et al: MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 61: 1600-1609, 2012.
16. Murakami Y, Toyoda H, Tanaka M, et al: The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 6: E16081, 2011.
17. Murakami Y, Toyoda H, Tanahashi T, et al: Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One 7: E48366, 2012.
18. Zhang H, Li QY, Guo ZZ, et al: Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 18: 5188-5196, 2012.
19. Pogribny IP, Starlard-Davenport A, Tryndyak VP, et al: Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 90: 1437-1446, 2010.
20. Cheung O, Puri P, Eicken C, et al: Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48: 1810-1820, 2008.
21. Alenghat T, Meyers K, Mullican SE, et al: Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456: 997-1000, 2008.
22. Fozzatti L, Park JW, Zhao L, Willingham MC and Cheng SY: Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS One 8: E67954, 2013.
23. Nan YM, Han F, Kong LB, et al: Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol 46: 358-369, 2011.
24. Jian-gao F; Chinese Liver Disease Association: Guidelines for management of nonalcoholic fatty liver disease: An updated and revised edition. Zhonghua Gan Zang Bing Za Zhi 18: 163-166, 2010.
25. Kleiner DE, Brunt EM, Van Natta M, et al; Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.
26. Livak KJ and Schmittgen TD: Analysis of Relative Gene Expression Data using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
27. Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM and Chan WY. Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene 30: 3404-3415, 2011.
28. Huang Da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
29. Galli A, Crabb DW, Ceni E, et al: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940, 2002.
30. Huang Da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.
31. Rottiers V and Näär AM: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13: 239-250, 2012.
32. Dávalos A, Goedeke L, Smibert P, et al: MiR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA 108: 9232-9237, 2011.
33. Poy MN, Eliasson L, Krutzfeldt J, et al: A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432: 226-230, 2004.
34. Esau C, Davis S, Murray SF, et al: MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98, 2006.
35. Chang J, Nicolas E, Marks D, et al: MiR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1: 106-113, 2004.
36. Krützfeldt J, Rajewsky N, Braich R, et al: Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689, 2005.
37. Li S, Chen X, Zhang H, et al: Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 50: 1756-1765, 2009.
38. Xu N, Zhang J, Shen C, et al: Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 423: 826-831, 2012.
39. Zhang Y, Fan KJ, Sun Q, et al: Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-beta signalling pathway. Nucleic Acids Res 40: 9286-9297, 2012.
40. Masotti A and Alisi A: Integrated bioinformatics analysis of microRNA expression profiles for an in-depth understanding of pathogenic mechanisms in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 27: 187-188, 2012.
41. Gäbele E, Brenner DA and Rippe RA: Liver fibrosis: Signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 8: D69-d77, 2003.
42. Geerts A: History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21: 311-335, 2001.
43. Milani S, Herbst H, Schuppan D, et al: Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology 98: 175-184, 1990.
44. Marra F: Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 31: 1120-1130, 1999.
45. Marra F, Efsen E, Romanelli RG, et al: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119: 466-478, 2000.
46. Li P, Fan W, Xu J, et al: Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 147: 815-826, 2011.
47. Ghisletti S, Huang W, Jepsen K, et al: Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev 23: 681-693, 2009.